Comparative safety profiles of risankizumab versus guselkumab: a pharmacovigilance study based on the FAERS database.

Front Pharmacol · 2026 · PMC12957254 · PMID 41788805

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Notably, the intestinal obstruction signal was highly significant in both the ≥65 years and 18–65 years age groups.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.